DRI Healthcare Trust (TSE:DHT.UN) Price Target Raised to C$24.00

DRI Healthcare Trust (TSE:DHT.UN) had its target price lifted by stock analysts at Stifel Nicolaus from C$23.00 to C$24.00 in a research note issued on Tuesday,BayStreet.CA reports. The firm currently has a “buy” rating on the stock. Stifel Nicolaus’ target price points to a potential upside of 33.26% from the stock’s current price.

A number of other research firms also recently weighed in on DHT.UN. Scotiabank lifted their price target on shares of DRI Healthcare Trust from C$25.00 to C$30.00 and gave the company a “sector outperform” rating in a research report on Tuesday, May 19th. National Bank Financial increased their price target on DRI Healthcare Trust from C$22.50 to C$23.50 and gave the stock an “outperform” rating in a research report on Tuesday, May 19th. Finally, Raymond James Financial raised their price objective on DRI Healthcare Trust from C$22.50 to C$23.50 and gave the stock a “strong-buy” rating in a research note on Monday. One investment analyst has rated the stock with a Strong Buy rating and four have assigned a Buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of C$24.80.

DRI Healthcare Trust Price Performance

DRI Healthcare Trust stock traded down C$0.50 during midday trading on Tuesday, hitting C$18.01. The company’s stock had a trading volume of 45,612 shares, compared to its average volume of 59,601. The company has a market cap of C$990.84 million, a price-to-earnings ratio of -20.01 and a beta of 0.47. DRI Healthcare Trust has a 1-year low of C$13.24 and a 1-year high of C$19.04. The company has a 50-day moving average price of C$17.17 and a two-hundred day moving average price of C$16.64.

About DRI Healthcare Trust

DRI Healthcare Trust is managed by DRI Capital Inc DRI a pioneer in global pharmaceutical royalty monetization. We provide uniquely favorable exposure for investors in the biopharma industry managing a diversified portfolio of interests in medicines that have a demonstrable positive impact on the world and aiming to acquire dependable patent-protected cash flow streams derived from the sales of those important drugs while limiting the risks and costs connected to drug development. DRI has developed a disciplined strategy predicated on actively sourcing royalty streams on medically necessary products and proudly work with multiple repeat deal partners.DRI Healthcare Trust is an unincorporated open-ended trust governed by the laws of the Province of Ontario pursuant to a declaration of trust dated October 21 2020 as amended.DRI Healthcare Trusts units are listed and trade on the Toronto Stock Exchange under DHT.UN in Canadian dollars and under DHT.U in U.S.